Early cancer detection is a key determinant of patient outcomes. Liquid biopsy is a sensitive diagnostic technology that uses peripheral blood to detect biomarkers for solid and liquid tumors. Current technologies detect circulating tumor cells and tumor DNA, but lack the sensitivity to identify cancer biomarkers from proteins present in the circulation. In this webinar, Klaus Pantel and Christoffer Gebhardt will discuss recent advances in liquid biopsy technology that allow researchers to detect protein biomarkers for diverse cancer types, including metastatic melanoma.

Topics to be covered

• The role of circulating protein biomarkers
• Technological advances and clinical applications of liquid biopsy
• Clinical trials for implementing liquid biopsy into clinical routine
  
  
  

Speaker Information: